Mylan recalls drug after problem uncovered with Indian supplier

A problem with a supplier in India has led Mylan ($MYL) to voluntarily recall a cancer drug in Canada. The maker of generic drugs has recalled one lot of methotrexate injection after the discovery of particulate in a unit. Mylan notified Health Canada of the potential manufacturing issue after it was uncovered during an inspection by a regulator of Onco Therapies, a unit of India's Strides Arcolab and one of its suppliers. Mylan made the decision to recall the product after its own investigation found the same problem in a sample of its product. Health Canada said it is looking at other Onco Therapies products shipped to Canada to see if there are any other issues. Report

Suggested Articles

Gilead Sciences will add 140 jobs to its Irish operations as part of an expansion to its Dublin distribution center, the Irish Times reported.

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

Moderna will delegate fill-finish duties for "hundreds of millions" of doses of its COVID-19 vaccine to Spain's Laboratorios Farmacéuticos Rovi.